Treatment of metastatic rhabdoid tumor of the kidney

J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):385-8. doi: 10.1097/00043426-200206000-00012.

Abstract

Metastatic rhabdoid tumor of the kidney (RTK) is a highly lethal malignancy; only one survivor with stage 4 disease has been reported. The authors reviewed the cases of two patients with metastatic RTK who had excellent responses to therapy. Both patients were treated with radiation therapy and alternating courses of ifosfamide, carboplatin, and etoposide (ICE) and vincristine, doxorubicin, and cyclophosphamide (VDC). The patients are without evidence of disease at 24 months and 12 months from the detection of metastasis. Alternating courses of ICE and VDC have activity against metastatic RTK. This combination of agents warrants prospective investigation in clinical trials.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / therapeutic use
  • Combined Modality Therapy
  • Cyclophosphamide / therapeutic use
  • Dactinomycin / therapeutic use
  • Etoposide / therapeutic use
  • Humans
  • Ifosfamide / therapeutic use
  • Infant
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / radiotherapy
  • Kidney Neoplasms / therapy*
  • Male
  • Neoplasm Staging
  • Rhabdoid Tumor / drug therapy
  • Rhabdoid Tumor / pathology
  • Rhabdoid Tumor / radiotherapy
  • Rhabdoid Tumor / therapy*
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Dactinomycin
  • Vincristine
  • Etoposide
  • Cyclophosphamide
  • Carboplatin
  • Ifosfamide

Supplementary concepts

  • ICE protocol 3
  • VAC protocol